Evidence map›Paper›PMID 21735164›Full record

ArticleEuropean journal of clinical pharmacology2012

Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study.

Trine Naalsund Andreassen, Ingrid Eftedal, Pål Klepstad, Andrew Davies, Kristin Bjordal, Staffan Lundström, Stein Kaasa, Ola Dale

Registry-linked trialOpen access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01813695 (Preemptive Genotyping of Children and Adolescents at Risk for Surgery and Subsequent Pain Management), which is not on this map. Cited by 42 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 5 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01813695 completednot on this mapstarted 2013, after this paper: background citation

Preemptive Genotyping of Children and Adolescents at Risk for Surgery and Subsequent Pain Management

TypeobservationalSponsorChildren's Hospital Medical Center, CincinnatiRan2013 to 2022Enrolled576ConditionsPainArmsPreemptive genotyping in medical record, Genotyping not included in electronic medical record
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 5 syntheses or guidelines pooled it, 113 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Guideline
  5. Guideline
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Trine Naalsund AndreassenPain and Palliation Research Group, Faculty of Medicine, Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, 7489, Trondheim, Norway. trine.n.andreassen@ntnu.no
Ingrid Eftedal
Pål Klepstad
Andrew Davies
Kristin Bjordal
Staffan Lundström
Stein Kaasa
Ola Dale
Norwegian University of Science and Technology · NOOslo University Hospital · NORoyal Surrey County Hospital · GBSt Olav's University Hospital · NOSwedish Foundation for Strategic Research · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveOpioids are recommended by the World Health Organization for moderate to severe cancer pain. Oxycodone is one of the most commonly used opioids and is metabolized in the liver by CYP3A4 and CYP2D6 enzymes. The aim of this cross-sectional study was to assess the relationship between oxycodone pharmacokinetics, pharmacodynamics and the CYP2D6 genotypes "poor metaboliser" (PM), "extensive metaboliser" (EM) and "ultra-rapid metaboliser" (URM) in a cohort of patients with cancer pain.

methodsThe patients were genotyped for the most common CYP2D6 variants and serum concentrations of oxycodone and metabolites were determined. Pain was assessed using the Brief Pain Inventory (BPI). The EORTC QLQ-C30 was used to assess the symptoms of tiredness and nausea. Cognitive function was assessed by the Mini Mental State (MMS) examination. Associations were examined by analyses of variance (ANOVA) and covariance (ANCOVA), or ordinal logistic regressions with and without covariates.

resultsThe sample consisted of 27 PM, 413 EM (including heterozygotes) and 10 URM. PM had lower oxymorphone and noroxymorphone serum concentrations and oxymorphone to oxycodone ratios than EM and URM. No differences between PM, EM and URM in pain intensity, nausea, tiredness or cognitive function was found.

conclusionCYP2D6 genotypes caused expected differences in pharmacokinetics, but they had no pharmacodynamic consequence. CYP2D6 genotypes did not influence pain control, the adverse symptoms nausea and sedation or the risk for cognitive failure in this study of patients treated with oxycodone for cancer pain.

Indexed as

Drug MonitoringPolymorphism, GeneticAdultAgedAged, 80 and overAnalgesics, OpioidBiotransformationChronic PainCohort StudiesCross-Sectional StudiesCytochrome P-450 CYP2D6Cytochrome P-450 CYP2D6 InhibitorsEuropeFemaleGenetic Association StudiesHumansAnalgesics, OpioidCytochrome P-450 CYP2D6Cytochrome P-450 CYP2D6 InhibitorsMorphinansnoroxymorphoneOxycodoneOxymorphone

Identifiers

PMID21735164
PMCPMC3249195
OpenAlexW2169863987

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.